New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
06:23 EDTQUREuniQure and Chiesi announce six year follow-up data from Glybera
uniQure and Chiesi Farmaceutici announced initial analysis of retrospectively collected individual patient data from LPLD patients treated with Glybera. The analysis covers follow-up data for up to six years post treatment for 13 patients, all of whom met indication requirements for the current labeling of Glybera in the EU. The review suggests that treatment with Glybera provides long-term beneficial effects with regard to the risk of encountering new pancreatitis events, including the occurrence of severe pancreatitis events. These results are in line with the trend exhibited in the first case note review performed up to 3 years after treatment with Glybera.
News For QURE From The Last 14 Days
Check below for free stories on QURE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 12, 2014
05:26 EDTQUREuniQure to host conference call
Conference call to discuss agreement to acquire InoCard will be held on August 12 at 8:30 am. Webcast Link
August 11, 2014
16:53 EDTQUREuniQure acquires InoCard in cash, stock
uniQure announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard founders Patrick Most and Hugo Katus will join uniQure as managing director of uniQure in Germany and chairman of the scientific advisory board, for cardiovascular diseases, respectively. Under the terms of the agreement, InoCard shareholders will receive an upfront payment of 3M, 1.5M in cash and 1.5M in uniQure stock, and certain success-based milestones and royalties.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use